ZBH vs GMED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 09, 2026

ZBH

28.9
AI Score
VS
GMED Wins

GMED

39.5
AI Score

Investment Advisor Scores

ZBH

29score
Recommendation
SELL

GMED

40score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZBH GMED Winner
Revenue 2.31B 6.33B ZBH
Net Income 417.04M 628.10M ZBH
Net Margin 18.0% 9.9% GMED
Operating Income 510.37M 1.01B ZBH
ROE 8.7% 4.9% GMED
ROA 7.5% 2.7% GMED
Total Assets 5.53B 23.54B ZBH
Cash 441.27M 399.90M GMED
Current Ratio 4.30 1.46 GMED
Free Cash Flow 564.16M 1.20B ZBH

Relative Price Performance (Last 90 Days)

ZBH 1M: +16.4% · 3M: +9.6% GMED 1M: -1.3% · 3M: -12.2%

Current Technical Phase

ZBH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 65.1 · Price: $107.32

GMED

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.5%) with fading momentum, RSI 46

RSI (14): 45.6 · Price: $75.23

Fundamentals Snapshot

Metric ZBH GMED
Market Cap — —
Forward P/E 12.0 14.1
Trailing P/E 27.4 18.8
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.7% 0.7%
Operating Margin 0.2% 0.2%
EPS 3.96 4.06
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.